Acute myeloid leukemia (AML) is a malignant disease of the hematopoietic system that originates from immature precursors of red blood cells, platelets and part of the white blood cells. While in healthy people the multiplication ...
Jan 24, 2023
0
42
Clinical characteristics, outcomes, and genetic features vary among different myelodysplastic syndrome (MDS) subtypes categorized using the 2022 International Consensus Classification (ICC), according to a study published ...
Jan 19, 2023
0
28
High doses of vitamin D alleviated symptoms for patients with toxic erythema of chemotherapy (TEC) significantly faster than current treatments, according to a Northwestern Medicine study published in JAMA Dermatology.
Jan 18, 2023
0
127
Severe inflammation weakens the body's ability to kill cancerous blood cells in people with acute myeloid leukemia (AML), a new study shows.
Jan 11, 2023
0
45
Researchers from the University of Bergen, Norway, have found a new method that within hours can predict if certain cancer patients will survive or not after chemotherapy.
Jan 10, 2023
0
21
Incorporation of an innovative patient-centered communication tool (UR-GOAL tool) is feasible for older adults with newly diagnosed acute myeloid leukemia (AML), according to study published online Dec. 19 in Cancer Medicine.
Dec 22, 2022
0
2
Despite California's success in reducing tobacco use, a new study published today in JAMA Network Open demonstrates the continued and significant burden tobacco inflicts on people with cancer.
Dec 14, 2022
2
51
Clonal hematopoiesis (CH) is a recently characterized condition in which the genetic mutations associated with leukemia and other blood cancers are found in the blood of individuals without cancer. This pre-cancerous state ...
Dec 13, 2022
0
8
Prior to allogeneic stem cell transplantation for the treatment of acute myeloid leukemia (AML), complete remission is currently still considered the gold standard of care.
Dec 12, 2022
0
17
Researchers at The Tisch Cancer Institute uncovered inflammatory markers that may predict which COVID-19 patients are more likely to respond to therapies like the anti-cancer drug pacritinib, according to phase 2 trial results ...
Dec 5, 2022
0
7
